ABSTRACT
Introduction Antivirals with differing mechanisms of action are needed for COVID-19 treatment; remdesivir is mainly used in hospitalized patients, but additional antivirals are needed in this setting. Ensitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan in November 2022, based on evidence of rapid symptom resolution in non-hospitalized patients, but confirmation of its efficacy in hospitalized patients is lacking.
Case presentations This case series reports outcomes for all patients who received ensitrelvir whilst hospitalized with SARS-CoV-2 infection at Rinku General Medical Center, Japan (November 2022– April 2023). Thirty-two hospitalized patients received five days of ensitrelvir treatment (375/125 mg). Mean age was 73.5 years and most patients had mild COVID-19. Patients exhibited various underlying diseases, most commonly hypertension (78.1%) and chronic kidney disease (25.0%). Seven (21.9%) patients were on hemodialysis. The most common concomitant medications were antihypertensives (59.4%) and corticosteroids (31.2%); two (6.3%) patients were being treated with rituximab; 27 (84.4%) patients had viral persistence following pre-treatment remdesivir failure. Following ensitrelvir treatment, all patients experienced clinical improvement as assessed by the investigator. No ICU admissions or deaths due to COVID-19 occurred. Viral clearance was recorded in 18 (56.3%) patients by day 5 and 25 (78.1%) patients at final measurement. No new safety signals were observed.
Discussion This case series represents ensitrelvir clinical efficacy in hospitalized patients with SARS-CoV-2 in a real-world setting. Most patients experienced persistent viral shedding despite pre-treatment with antivirals, and most were considered high-risk due to underlying conditions. Despite this, no patients experienced progression of COVID-19 to severe or critical disease, including those who failed prior remdesivir treatment. The antiviral activity of ensitrelvir demonstrated here indicates it is a viable treatment option for SARS-CoV-2 infection in this setting.
Conclusion Ensitrelvir was associated with potent antiviral activity and positive clinical outcomes in high-risk, hospitalized patients with various comorbidities.
Trial Registration UMIN000051300
Why carry out this study?
Real-world evidence of ensitrelvir for the treatment of COVID-19, especially in inpatient settings, is required.
This was a retrospective cohort analysis, consisting of 32 high-risk hospitalized patients with a range of disease severities and comorbidities, including patients who had experienced remdesivir treatment failure.
What was learned from the study?
All patients experienced clinical improvement following ensitrelvir treatment, without any worsening COVID-19.
Viral clearance was documented in 78.1% of patients at final viral measurement.
No new safety signals of ensitrelvir were observed in this analysis.
Competing Interest Statement
Masaya Yamato has received lecture fees from, and serves as an advisor for, Shionogi & Co., Ltd.. Masahiro Kinoshita, Shogo Miyazawa and Takuhiro Sonoyama are employees of Shionogi & Co., Ltd.. Masayuki Seki and Tomoki Mizuno have nothing to disclose. This study was supported by Shionogi & Co., Ltd. In the form of all costs associated with the development and publication of this manuscript.
Funding Statement
Editorial assistance in the preparation of this manuscript, under the direction of the authors, was provided by Ian McAllister, BSc, of Ashfield MedComms, an Inizio Company, funded by Shionogi & Co., Ltd., and complied with Good Publication Practice (GPP) guidelines (DeTora LM, et al. Ann Intern Med 2022;175:1298).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with the Declaration of Helsinki, and approved by the Rinku General Medical Center Clinical Research Ethics Committee (2-23 Rinku Oraikita, Izumisano City 598-0048; protocol ID: 2023FY-I-001; date of approval 18 May 2023). Patient consent was acquired using an opt-out procedure and no data were included that would allow identification of individual patients. This study was registered in UMIN Clinical Trials Registry (study ID: UMIN000051300).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All associated data are published within the main body of the manuscript and supplementary materials.
